title: [Limbal transplantation: multicenter retrospective case series analysis].
abstract: OBJECTIVE
  To report the results of limbal transplantation (LT) in patients with limbal stem cell deficiency (LSCD) in the context of ocular surface diseases.
  
  
  METHODS
  A multicenter (5 centers) retrospective case series analysis of patients who underwent LT between 1996 and 2004 was performed. Data were collected by the same researcher using a customized database. Success was defined by the absence of a persistent corneal epithelial defect, on-going inflammation or recurrence of a pterygium.
  
  
  RESULTS
  Data from 72 LT performed in 61 patients (65 eyes) with a mean follow-up of 20.8 months (SD 23.5; range, 3-115) were analyzed. There were 33 males and 28 females with a mean age of 55.8 years (SD: 15.6; range, 20-89). Fifty-eight (80.6%) LT were autografts (40 pterygia, 12 alkali burns, 3 iatrogenic cases, 2 viral infections, 1 neoplasia case) and 14 (19.4%) were allografts from cadaveric donors (7 immune-based disorders, 6 alkali burns, 1 iatrogenic case); all patients receiving allografts also received systemic immunosuppression. Of the total number of LT, 48 (66.7%) were successful. This proportion increased to 81.0% (47/58) when autografts were used. However, only 7.1% (1/14) of all allografts were successful. The success rate was higher (80.0%) when performed for a pterygium and lower when done for immune-based inflammation (14.3%).
  
  
  CONCLUSIONS
  Autograft tissue for LT is always preferable to allografts to surgically treat LSCD, as clinical success is significantly higher, and systemic immunosuppression is avoided. As expected, immune-based disorders are the most difficult cases to treat. LT has been shown to be an excellent option for recurrent pterygium, although prospective studies need to be performed to further corroborate these results.
authors.affiliation: IOBA, Universidad de Valladolid, Valladolid, España.
authors.forename: J
authors.initials: J
authors.lastname: Torres
authors.forename: I
authors.initials: I
authors.lastname: Fernández
authors.forename: M J
authors.initials: MJ
authors.lastname: Quadrado
authors.forename: J
authors.initials: J
authors.lastname: Murta
authors.forename: J
authors.initials: J
authors.lastname: Herreras
authors.forename: M T
authors.initials: MT
authors.lastname: Rodríguez-Ares
authors.forename: J M
authors.initials: JM
authors.lastname: Benítez-del-Castillo
authors.forename: J
authors.initials: J
authors.lastname: Alió
authors.forename: M F
authors.initials: MF
authors.lastname: Muñoz
authors.forename: M
authors.initials: M
authors.lastname: Calonge
mesh_terms: D000328:Adult; D053687:Adult Stem Cells / Q000637:transplantation*; D000368:Aged; D000369:Aged, 80 and over; D016039:Corneal Transplantation / Q000379:methods*; D016208:Databases, Factual; D004847:Epithelial Cells / Q000166:cytology; D005126:Eye Burns / Q000601:surgery; D015828:Eye Infections, Viral / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016850:Limbus Corneae / Q000166:cytology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011625:Pterygium / Q000601:surgery*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome